Trial results

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07801820 on ClinicalTrials.gov · last registry update 2026-09-03

An unusually large phase 2: 240 participants, more than double the 114 typical for the stage. Due to report March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Shanghai Minwei Biotechnology Co., Ltd

Sponsor type

Industry

Enrollment

240

Started

2026-06-23

Primary completion

2027-03 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo

Conditions studied

Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.